The most significant publications in peritoneal dialysis I (PD) in 2012 are undoubtedly those from the balAHZ study. This randomized controlled trial conducted in Australia, New Zealand, and Singapore looked at the effect of Balance—the neutral-pH, double-pouch PD solution lowin glucose degradation products (GDPs) from Fresenius Medical Care (Bad Homburg, Germany)—on important clinical outcomes in 185 incident PD patients. Results from this important study have appeared in three publications. The first, published in the Journal of the American Society of Nephrotogy, looked atboth the primary outcome of residual renalfunction (RRF) and the secondary outcome of peritonitis (1). The second, published in Mephroiogy Dialysis Transplantation, looked at peritoneal membrane function (2). The third, which appears in this issue of Peritoneal Dialysis International (PDI), looks in more detail at the peritonitis outcome (3).
展开▼
机译：毫无疑问，2012年腹膜透析I（PD）中最重要的出版物来自balAHZ研究。这项在澳大利亚，新西兰和新加坡进行的随机对照试验研究了Balance（对来自Fresenius Medical Care（德国巴特洪堡）的低葡萄糖降解产物（GDP）的中性pH双袋PD溶液）的重要影响。 185例PD患者的临床结局。这项重要研究的结果发表在三份出版物中。第一篇发表在《美国肾脏病学会杂志》上，研究了残余肾功能（RRF）的主要结局和腹膜炎的次要结局（1）。第二篇发表在《肾透析透析移植》中，着眼于腹膜功能（2）。第三期出现在本期《腹膜透析国际》（PDI）上，详细探讨了腹膜炎的预后（3）。
展开▼
